J. Bagel

发表

A review of phototherapy protocols for psoriasis treatment.

S. Feldman, W. Lapolla, C. Halvorson, 2011, Journal of the American Academy of Dermatology.

Utilization of narrow-band ultraviolet light B therapy and etanercept for the treatment of psoriasis (UNITE): efficacy, safety, and patient-reported outcomes.

C. Elmets, A. Menter, J. Koo, 2008, Journal of drugs in dermatology : JDD.

IGAxBSA composite for assessing disease severity and response in patients with atopic dermatitis

A. Paller, B. Shumel, J. Bagel, 2021, The British journal of dermatology.

Improvement of atopic dermatitis with dupilumab occurs equally well across different anatomical regions: data from phase III clinical trials

T. Bieber, M. Worm, M. Kawashima, 2019, The British journal of dermatology.

Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis.

B. Strober, M. Lebwohl, A. Kimball, 2015, The New England journal of medicine.

T-Cell Targeted Therapy: Alefacept and Efalizumab

J. Bagel, 2014 .

Decision points for the initiation of systemic treatment for psoriasis.

S. Feldman, A. Menter, J. Koo, 2005, Journal of the American Academy of Dermatology.

Repeat courses of intravenous alefacept in patients with chronic plaque psoriasis provide consistent safety and efficacy

A. Menter, C. Ellis, N. Lowe, 2003, International journal of dermatology.

National Psoriasis Foundation clinical consensus on disease severity.

Elizabeth J Horn, B. Strober, M. Lebwohl, 2007, Archives of dermatology.

From the Medical Board of the National Psoriasis Foundation: monitoring and vaccinations in patients treated with biologics for psoriasis.

B. Strober, M. Lebwohl, A. Kimball, 2008, Journal of the American Academy of Dermatology.

Treatment of intertriginous psoriasis: from the Medical Board of the National Psoriasis Foundation.

M. Lebwohl, E. Horn, N. Korman, 2009, Journal of the American Academy of Dermatology.

A multicenter dose-escalation trial with denileukin diftitox (ONTAK, DAB(389)IL-2) in patients with severe psoriasis.

A. Gottlieb, W. T. Garland, C. Guzzo, 2001, Journal of the American Academy of Dermatology.

Administration of DAB389IL-2 to patients with recalcitrant psoriasis: a double-blind, phase II multicenter trial.

M. Holick, D. Fivenson, W. T. Garland, 1998, Journal of the American Academy of Dermatology.

Establishing a practical and effective psoriasis treatment center.

J. Bagel, 2000, Dermatologic clinics.

Efficacy, safety, usability, and acceptability of risankizumab 150 mg formulation administered by prefilled syringe or by an autoinjector for moderate to severe plaque psoriasis

A. Soliman, K. Gordon, A. Blauvelt, 2021, The Journal of dermatological treatment.

The National Psoriasis Foundation psoriasis treatment targets in real‐world patients: prevalence and association with patient‐reported outcomes in the Corrona Psoriasis Registry

M. Mason, J. Greenberg, L. Perez Chada, 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

Superior efficacy of calcipotriene and betamethasone dipropionate aerosol foam versus ointment in patients with psoriasis vulgaris – A randomized phase II study

J. Koo, S. Tyring, J. Villumsen, 2015, The Journal of dermatological treatment.

Secukinumab maintains superiority over ustekinumab in clearing skin and improving quality of life in patients with moderate to severe plaque psoriasis: 52‐week results from a double‐blind phase 3b trial (CLARITY)

M. Lebwohl, A. Blauvelt, J. Bagel, 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

Secukinumab is Superior to Ustekinumab in Clearing Skin in Patients with Moderate to Severe Plaque Psoriasis (16-Week CLARITY Results)

M. Lebwohl, A. Blauvelt, J. Bagel, 2018, Dermatology and Therapy.

Serious infections in patients with self-reported psoriatic arthritis from the Psoriasis Longitudinal Assessment and Registry (PSOLAR) treated with biologics

A. Gottlieb, C. Ritchlin, Y. Poulin, 2019, BMC Rheumatology.

Dupilumab provides important clinical benefits to patients with atopic dermatitis who do not achieve clear or almost clear skin according to the Investigator's Global Assessment: a pooled analysis of data from two phase III trials

J. Silverberg, M. Ardeleanu, E. Simpson, 2019, The British journal of dermatology.

Optimizing topical therapies for treating psoriasis: a consensus conference.

B. Elewski, M. Lebwohl, S. Feldman, 2010, Cutis.

Consensus guidelines for the management of plaque psoriasis.

B. Strober, A. Gottlieb, M. Lebwohl, 2012, Archives of dermatology.

Dietary Recommendations for Adults With Psoriasis or Psoriatic Arthritis From the Medical Board of the National Psoriasis Foundation: A Systematic Review

A. Gottlieb, M. Lebwohl, A. Armstrong, 2018, JAMA dermatology.

Combining biologic therapies with other systemic treatments in psoriasis: evidence-based, best-practice recommendations from the Medical Board of the National Psoriasis Foundation.

A. Armstrong, A. V. Van Voorhees, J. Bagel, 2015, JAMA dermatology.

15340 Long-term treatment with secukinumab led to sustained clinical improvement and normalization of inflammatory markers in patients with psoriasis

A. Armstrong, F. Kianifard, A. Blauvelt, 2020 .

Efficacy of guselkumab versus secukinumab in subpopulations of patients with moderate-to-severe plaque psoriasis: results from the ECLIPSE study

A. Armstrong, K. Reich, Y. You, 2021, The Journal of dermatological treatment.

Patient‐reported outcomes in moderate‐to‐severe plaque psoriasis with scalp involvement: results from a randomized, double‐blind, placebo‐controlled study of etanercept

S. Tyring, C. Lynde, G. Kricorian, 2013, Journal of the European Academy of Dermatology and Venereology : JEADV.

Moderate to severe plaque psoriasis with scalp involvement: a randomized, double-blind, placebo-controlled study of etanercept.

S. Tyring, C. Lynde, G. Kricorian, 2012, Journal of the American Academy of Dermatology.

The Role of a Gluten-Free Diet in Psoriasis

J. Bagel, Margaret L. Rush, 2011 .

Baseline Demographics and Severity and Burden of Atopic Dermatitis in Adult Patients Initiating Dupilumab Treatment in a Real-World Registry (PROSE)

M. Ardeleanu, Zhen Chen, J. Chao, 2022, Dermatology and Therapy.

Adalimumab for treatment of moderate to severe chronic plaque psoriasis of the hands and feet: efficacy and safety results from REACH, a randomized, placebo-controlled, double-blind trial.

K. Papp, C. Leonardi, S. Tyring, 2011, Archives of dermatology.

S. Feldman, J. Bagel, S. Namak, 2017, The American journal of the medical sciences.

Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial *

K. Reich, M. Augustin, G. Bruin, 2022, The British journal of dermatology.

Topical therapies for the treatment of plaque psoriasis.

J. Bagel, 2009, Cutis.

Adjunctive Use of Calcipotriene/Betamethasone Dipropionate Foam in a Real-World Setting Curtails the Cost of Biologics Without Reducing Efficacy in Psoriasis

J. Bagel, E. Nelson, James Zapata, 2020, Dermatology and Therapy.

Effect of Roflumilast Cream vs Vehicle Cream on Chronic Plaque Psoriasis: The DERMIS-1 and DERMIS-2 Randomized Clinical Trials.

M. Lebwohl, Z. Draelos, M. Gooderham, 2022, JAMA.

From the Medical Board of the National Psoriasis Foundation: The risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapies.

M. Lebwohl, A. Blauvelt, R. Nijhawan, 2014, Journal of the American Academy of Dermatology.

Hemorrhagic bullae associated with Morganella morganii septicemia.

M. Grossman, J. Bagel, 1985, Journal of the American Academy of Dermatology.

Efficacy and safety of ixekizumab in a phase III, randomized, double‐blind, placebo‐controlled study in paediatric patients with moderate‐to‐severe plaque psoriasis (IXORA‐PEDS)†

A. Paller, E. Edson-Heredia, K. Papp, 2020, The British journal of dermatology.

Enthesitis and Dactylitis in Psoriatic Disease: A Guide for Dermatologists

S. Schwartzman, J. Bagel, 2018, American Journal of Clinical Dermatology.

Open‐label study of etanercept treatment in patients with moderate‐to‐severe plaque psoriasis who lost a satisfactory response to adalimumab

D. Collier, S. Tyring, G. Kricorian, 2017, The British journal of dermatology.

Treatment of Medicare Patients with Moderate-to-Severe Psoriasis who Cannot Afford Biologics or Apremilast

A. Gottlieb, A. Orbai, Nicola E. Natsis, 2019, American Journal of Clinical Dermatology.

Efficacy and Safety of Apremilast in Systemic- and Biologic-Naive Patients With Moderate Plaque Psoriasis: 52-Week Results of UNVEIL.

M. Lebwohl, K. Duffin, L. Stein Gold, 2018, Journal of drugs in dermatology : JDD.

Efficacy and Safety of Apremilast in Patients With Moderate Plaque Psoriasis With Lower BSA: Week 16 Results from the UNVEIL Study.

B. Strober, M. Lebwohl, K. Callis Duffin, 2017, Journal of drugs in dermatology : JDD.

Apremilast and Narrowband Ultraviolet-B Combination Therapy for Treating Moderate-to-Severe Plaque Psoriasis.

B. Keegan, J. Bagel, E. Nelson, 2017, Journal of drugs in dermatology : JDD.

Effect of baseline disease severity on achievement of treatment target with apremilast: results from a pooled analysis

B. Strober, M. Lebwohl, A. Menter, 2021, Journal of the European Academy of Dermatology and Venereology : JEADV.

Evaluation of the Physician Global Assessment and Body Surface Area Composite Tool for Assessing Psoriasis Response to Apremilast Therapy: Results from ESTEEM 1 and ESTEEM 2.

A. Gottlieb, K. Papp, K. Duffin, 2017, Journal of drugs in dermatology : JDD.

The effect of secukinumab on moderate‐to‐severe scalp psoriasis: Results of a 24‐week, randomized, double‐blind, placebo‐controlled phase 3b study

M. Lebwohl, L. Ferris, F. Kianifard, 2017, Journal of the American Academy of Dermatology.

From the Medical Board of the National Psoriasis Foundation: Treatment targets for plaque psoriasis

A. Gottlieb, M. Lebwohl, A. Armstrong, 2017, Journal of the American Academy of Dermatology.

Efficacy and Safety of Apremilast in Patients with Moderate Plaque Psoriasis with Lower BSA (UNVEIL Phase IV Study)

B. Strober, M. Lebwohl, K. Duffin, 2017 .

Efficacy and Safety of Calcipotriene Plus Betamethasone Dipropionate Aerosol Foam in Patients With Psoriasis Vulgaris--a Randomized Phase III Study (PSO-FAST).

C. Leonardi, Zhenyi Xu, D. Pariser, 2015, Journal of drugs in dermatology : JDD.

Serlopitant for Psoriatic Pruritus: a Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial.

M. Lebwohl, M. Spellman, G. Yosipovitch, 2020, Journal of the American Academy of Dermatology.

Phase 3 Trials of Tapinarof Cream for Plaque Psoriasis.

B. Strober, M. Lebwohl, S. Piscitelli, 2021, The New England journal of medicine.

A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 12‐week efficacy, safety and speed of response from a randomized, double‐blinded trial†

Kelly N. Taylor, Constance M. Brown, B. Elewski, 2019, The British journal of dermatology.

Bimekizumab versus Adalimumab in Plaque Psoriasis.

A. Armstrong, K. Papp, K. Reich, 2021, The New England journal of medicine.

Next-generation biologics in the management of plaque psoriasis: a literature review of IL-17 inhibition.

J. Bagel, P. Yamauchi, 2015, Journal of drugs in dermatology : JDD.

Phase 3, open‐label, randomized study of the pharmacokinetics, efficacy and safety of ixekizumab following subcutaneous administration using a prefilled syringe or an autoinjector in patients with moderate‐to‐severe plaque psoriasis (UNCOVER‐A)

L. Mallbris, F. Zhao, K. Callis Duffin, 2016, Journal of the European Academy of Dermatology and Venereology : JEADV.

Brodalumab in the treatment of moderate-to-severe psoriasis in patients who have previously failed treatment with anti-interleukin-17A therapies.

M. Lebwohl, G. Singer, S. Kim, 2019, Journal of the American Academy of Dermatology.

Alefacept in combination with ultraviolet B phototherapy for the treatment of chronic plaque psoriasis: results from an open-label, multicenter study.

M. Sweetser, J. Koo, B. Ticho, 2006, Journal of drugs in dermatology : JDD.

Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 POETYK PSO-2 trial.

B. Strober, K. Papp, P. Foley, 2022, Journal of the American Academy of Dermatology.

Efficacy and safety of apremilast in patients with moderate‐to‐severe plaque psoriasis of the scalp: results up to 32 weeks from a randomized, phase III study

B. Strober, M. Lebwohl, K. Papp, 2021, The British journal of dermatology.

Transitioning Biologic and Systemic Therapies in Psoriatic Patients

J. Bagel, 2018 .

Immunogenicity and Skin Clearance Recapture in Clinical Studies of Brodalumab.

M. Lebwohl, J. Bagel, R. Israel, 2020, Journal of the American Academy of Dermatology.

Apremilast

J. Bagel, E. Nelson, 2019, Reactions Weekly.

Roflumilast Cream 0.3% Improved the Severity and Impact of Itch in Patients With Chronic Plaque Psoriasis in the Phase 3 DERMIS-1 and DERMIS-2 Studies

M. Lebwohl, M. Gooderham, K. Papp, 2021, SKIN The Journal of Cutaneous Medicine.

Once-Daily Roflumilast Cream 0.3%, a Potent Phosphodiesterase-4 Inhibitor, Provided Safe and Effective Treatment of Psoriasis in the DERMIS-1 and DERMIS-2 Phase 3 Trials

M. Lebwohl, Z. Draelos, M. Gooderham, 2021, SKIN The Journal of Cutaneous Medicine.

Halobetasol propionate for the management of psoriasis.

G. Han, J. Bagel, Q. Thibodeaux, 2020, Cutis.

Adalimumab plus narrowband ultraviolet B light phototherapy for the treatment of moderate to severe psoriasis.

J. Bagel, 2011, Journal of drugs in dermatology : JDD.

Bimekizumab Efficacy and Safety versus Adalimumab in Patients with Moderate to Severe Plaque Psoriasis: Results from a Multicenter, Randomized, Double-Blinded Active Comparator-Controlled Phase 3 Trial (BE SURE)

K. Papp, K. Reich, A. Blauvelt, 2021 .

Usability of a novel disposable autoinjector device for ixekizumab: results from a qualitative study and an open-label clinical trial, including patient-reported experience

Fangyi Zhao, D. Shrom, Kristina Callis Duffin, 2016, Medical devices.

Safety and Efficacy of a Fixed Combination Halobetasol and Tazarotene Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: A Pooled Analysis of Two Phase 3 Studies.

J. Weiss, E. Tanghetti, L. Stein Gold, 2018, Journal of Drugs in Dermatology.

Combination approaches using Topical Vitamin D for Psoriasis

J. Bagel, 2013 .

Open-Label, Observational Pilot Study Evaluating Desoximetasone Topical Spray 0.25% Twice Daily in Patients With Psoriasis Being Treated With Biologic Agents

B. Keegan, J. Bagel, E. Nelson, 2018 .

Dose escalation and associated costs in biologic treatment of psoriasis based on real-world data

Jashin J. Wu, B. Glick, Xue Song, 2021, Journal of medical economics.

LCD plus NB-UVB reduces time to improvement of psoriasis vs. NB-UVB alone.

J. Bagel, 2009, Journal of drugs in dermatology : JDD.

The Evolving Use of Phototherapy in Combination with Other Treatments for Chronic Plaque Psoriasis

J. Bagel, 2005 .

A Prospective, Open-Label Study Evaluating Adjunctive Calcipotriene 0.005%/Betamethasone Dipropionate 0.064% Foam in Psoriasis Patients With Inadequate Response to Biologic Therapy.

J. Bagel, E. Nelson, James Zapata, 2018, Journal of drugs in dermatology : JDD.

The Aerosol Foam Formulation of the Fixed Combination Calcipotriene Plus Betamethasone Dipropionate Improves the Health-Related Quality of Life in Patients With Psoriasis Vulgaris: Results from the Randomized PSO-FAST Study.

C. Leonardi, Zhenyi Xu, D. Pariser, 2016, Journal of drugs in dermatology : JDD.

Subcutaneous nodules in Pseudomonas sepsis.

M. Grossman, J. Bagel, 1986, The American journal of medicine.

Plaque psoriasis management: a 2013 update

B. Keegan, J. Bagel, 2013 .

Tralokinumab Does Not Impact Vaccine-induced Immune Responses: Results From a 30-week, Randomized, Placebo-controlled Trial in Adults With Moderate-to-severe Atopic Dermatitis.

P. Almgren, J. Merola, J. Bagel, 2021, Journal of the American Academy of Dermatology.

A Retrospective Review of Patients' Response to Biologic Therapy for Psoriasis.

J. Bagel, B. Butler, E. Nelson, 2021, Journal of Drugs in Dermatology.

Outcomes of Biologic Use in Asian Compared with Non-Hispanic White Adult Psoriasis Patients from the CorEvitas Psoriasis Registry

R. Burge, Gang Wang, R. McLean, 2022, Dermatology and Therapy.

A Machine Learning-Based Test for Predicting Response to Psoriasis Biologics

A. Menter, T. Dickerson, Byung-in Lee, 2021, SKIN The Journal of Cutaneous Medicine.

Betamethasone dipropionate spray 0.05% alleviates troublesome symptoms of plaque psoriasis.

L. Stein Gold, J. Bagel, K. Allenby, 2020, Cutis.

Combining Topical Psoriasis Treatment to Enhance Systemic and Phototherapy: A Review of the Literature.

J. Bagel, L. Gold, 2017, Journal of drugs in dermatology : JDD.

27434 Early trends of disease improvement in adult patients with atopic dermatitis treated with dupilumab: Real-world data from the PROSE registry

G. Yosipovitch, R. Lin, D. Pariser, 2021 .

Dietary Recommendations for Adults With Psoriasis or Psoriatic Arthritis From the Medical Board of the National Psoriasis Foundation: A Systematic Review

A. Gottlieb, M. Lebwohl, A. Armstrong, 2018, JAMA dermatology.

Weight loss in obese patients with psoriasis can be successfully achieved during a course of phototherapy

A. Kimball, J. Bagel, J. Bagel, 2011, Journal of the European Academy of Dermatology and Venereology : JEADV.

Psoriasis improvements and inflammatory biomarker normalization with secukinumab: the randomized ObePso-S study.

F. Kianifard, A. Blauvelt, S. Tyring, 2023, Journal of dermatological science.

Combining biologic therapies with other systemic treatments in psoriasis: evidence-based, best-practice recommendations from the Medical Board of the National Psoriasis Foundation.

A. Armstrong, A. V. Van Voorhees, J. Bagel, 2015, JAMA dermatology.

Serious Gastrointestinal-Related Adverse Events Among Psoriasis Patients Treated With Guselkumab in VOYAGE 1 and VOYAGE 2.

M. Lebwohl, C. Griffiths, K. Reich, 2021, Journal of drugs in dermatology : JDD.